Literature DB >> 20430122

Optimal vaccine stockpile design for an eradicated disease: application to polio.

Radboud J Duintjer Tebbens1, Mark A Pallansch, James P Alexander, Kimberly M Thompson.   

Abstract

Eradication of a disease promises significant health and financial benefits. Preserving those benefits, hopefully in perpetuity, requires preparing for the possibility that the causal agent could re-emerge (unintentionally or intentionally). In the case of a vaccine-preventable disease, creation and planning for the use of a vaccine stockpile becomes a primary concern. Doing so requires consideration of the dynamics at different levels, including the stockpile supply chain and transmission of the causal agent. This paper develops a mathematical framework for determining the optimal management of a vaccine stockpile over time. We apply the framework to the polio vaccine stockpile for the post-eradication era and present examples of solutions to one possible framing of the optimization problem. We use the framework to discuss issues relevant to the development and use of the polio vaccine stockpile, including capacity constraints, production and filling delays, risks associated with the stockpile, dynamics and uncertainty of vaccine needs, issues of funding, location, and serotype dependent behavior, and the implications of likely changes over time that might occur. This framework serves as a helpful context for discussions and analyses related to the process of designing and maintaining a stockpile for an eradicated disease. (c) 2010 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 20430122     DOI: 10.1016/j.vaccine.2010.04.001

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response.

Authors:  Kimberly M Thompson; Gregory S Wallace; Radboud J Duintjer Tebbens; Philip J Smith; Albert E Barskey; Mark A Pallansch; Kathleen M Gallagher; James P Alexander; Gregory L Armstrong; Stephen L Cochi; Steven G F Wassilak
Journal:  Public Health Rep       Date:  2012 Jan-Feb       Impact factor: 2.792

2.  Preeradication vaccine policy options for poliovirus infection and disease control.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Jong-Hoon Kim; Stephen L Cochi
Journal:  Risk Anal       Date:  2013-03-05       Impact factor: 4.000

3.  Modeling poliovirus risks and the legacy of polio eradication.

Authors:  Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-28       Impact factor: 4.000

Review 4.  Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Konstantin M Chumakov; Neal A Halsey; Tapani Hovi; Philip D Minor; John F Modlin; Peter A Patriarca; Roland W Sutter; Peter F Wright; Steven G F Wassilak; Stephen L Cochi; Jong-Hoon Kim; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-28       Impact factor: 4.000

5.  Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination.

Authors:  Kasper H Kisjes; Radboud J Duintjer Tebbens; Gregory S Wallace; Mark A Pallansch; Stephen L Cochi; Steven G F Wassilak; Kimberly M Thompson
Journal:  J Infect Dis       Date:  2014-11-01       Impact factor: 5.226

Review 6.  Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication.

Authors:  Jean Guo; Sara Bolivar-Wagers; Nivedita Srinivas; Marisa Holubar; Yvonne Maldonado
Journal:  Vaccine       Date:  2015-01-16       Impact factor: 3.641

Review 7.  Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.

Authors:  Dominika A Kalkowska; Mark A Pallansch; Stephen L Cochi; Stephanie D Kovacs; Steven G F Wassilak; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-07-06       Impact factor: 4.000

8.  Development of thermostable lyophilized inactivated polio vaccine.

Authors:  Heleen Kraan; Paul van Herpen; Gideon Kersten; Jean-Pierre Amorij
Journal:  Pharm Res       Date:  2014-04-24       Impact factor: 4.200

Review 9.  Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.

Authors:  Kimberly M Thompson; Dominika A Kalkowska
Journal:  Risk Anal       Date:  2020-04-27       Impact factor: 4.000

10.  An economic analysis of poliovirus risk management policy options for 2013-2052.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Stephen L Cochi; Steven G F Wassilak; Kimberly M Thompson
Journal:  BMC Infect Dis       Date:  2015-09-24       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.